Cyclo Therapeutics (CYTH) Competitors $0.79 +0.00 (+0.58%) As of 01/17/2025 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CYTH vs. BGM, RANI, AADI, IKNA, INCR, ANL, AVTE, PMVP, AVTX, and UNCYShould you be buying Cyclo Therapeutics stock or one of its competitors? The main competitors of Cyclo Therapeutics include Qilian International Holding Group (BGM), Rani Therapeutics (RANI), Aadi Bioscience (AADI), Ikena Oncology (IKNA), InterCure (INCR), Adlai Nortye (ANL), Aerovate Therapeutics (AVTE), PMV Pharmaceuticals (PMVP), Avalo Therapeutics (AVTX), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical products" industry. Cyclo Therapeutics vs. Qilian International Holding Group Rani Therapeutics Aadi Bioscience Ikena Oncology InterCure Adlai Nortye Aerovate Therapeutics PMV Pharmaceuticals Avalo Therapeutics Unicycive Therapeutics Cyclo Therapeutics (NASDAQ:CYTH) and Qilian International Holding Group (NASDAQ:BGM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and community ranking. Does the MarketBeat Community believe in CYTH or BGM? Cyclo Therapeutics received 10 more outperform votes than Qilian International Holding Group when rated by MarketBeat users. CompanyUnderperformOutperformCyclo TherapeuticsOutperform Votes1071.43% Underperform Votes428.57% Qilian International Holding GroupN/AN/A Does the media favor CYTH or BGM? In the previous week, Cyclo Therapeutics' average media sentiment score of 0.00 equaled Qilian International Holding Group'saverage media sentiment score. Company Overall Sentiment Cyclo Therapeutics Neutral Qilian International Holding Group Neutral Do analysts rate CYTH or BGM? Cyclo Therapeutics currently has a consensus price target of $0.95, indicating a potential upside of 20.87%. Given Cyclo Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Cyclo Therapeutics is more favorable than Qilian International Holding Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Qilian International Holding Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of CYTH or BGM? 68.6% of Cyclo Therapeutics shares are held by institutional investors. 29.8% of Cyclo Therapeutics shares are held by company insiders. Comparatively, 58.7% of Qilian International Holding Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, CYTH or BGM? Cyclo Therapeutics has a beta of -0.49, indicating that its stock price is 149% less volatile than the S&P 500. Comparatively, Qilian International Holding Group has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Is CYTH or BGM more profitable? Qilian International Holding Group has a net margin of 0.00% compared to Cyclo Therapeutics' net margin of -2,847.19%. Company Net Margins Return on Equity Return on Assets Cyclo Therapeutics-2,847.19% N/A -307.16% Qilian International Holding Group N/A N/A N/A Which has better earnings & valuation, CYTH or BGM? Qilian International Holding Group has higher revenue and earnings than Cyclo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclo Therapeutics$1.08M20.94-$20.06M-$0.90-0.87Qilian International Holding Group$46.47M1.51-$7.78MN/AN/A SummaryCyclo Therapeutics and Qilian International Holding Group tied by winning 6 of the 12 factors compared between the two stocks. Get Cyclo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTH vs. The Competition Export to ExcelMetricCyclo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.61M$2.96B$5.21B$9.14BDividend YieldN/A1.91%5.13%4.02%P/E Ratio-0.8745.5689.3417.36Price / Sales20.94275.871,240.0477.11Price / CashN/A192.9043.7535.97Price / Book3.743.965.314.79Net Income-$20.06M-$41.02M$122.54M$225.00M7 Day Performance19.07%0.19%0.59%2.62%1 Month Performance24.76%-1.72%2.55%3.81%1 Year Performance-51.48%-2.23%25.29%20.10% Cyclo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTHCyclo Therapeutics1.7911 of 5 stars$0.79+0.6%$0.95+20.9%-51.5%$22.61M$1.08M-0.879BGMQilian International Holding GroupN/A$10.32-9.1%N/AN/A$74.58M$29.87M0.00298Positive NewsGap DownRANIRani Therapeutics3.6358 of 5 stars$1.30+4.0%$11.71+801.1%-62.0%$74.48M$2.72M-1.23110News CoveragePositive NewsAADIAadi Bioscience1.3394 of 5 stars$3.02-16.1%$1.67-44.8%+82.8%$74.43M$25.07M-1.3240Positive NewsIKNAIkena Oncology2.4465 of 5 stars$1.54-1.3%$3.00+94.8%-1.3%$74.32M$659,000.00-1.2570INCRInterCure0.2502 of 5 stars$1.63-2.7%N/A+19.7%$74.28M$272.67M0.00350ANLAdlai Nortye1.653 of 5 stars$1.98-0.5%$9.00+354.5%-76.5%$73.06M$5M0.00127AVTEAerovate Therapeutics1.0591 of 5 stars$2.50-2.0%$2.25-10.0%-87.3%$72.19MN/A-0.8420Positive NewsPMVPPMV Pharmaceuticals2.2488 of 5 stars$1.39-4.8%$5.50+295.7%-14.9%$71.93MN/A-1.3950Positive NewsAVTXAvalo Therapeutics4.0424 of 5 stars$6.87-1.9%$40.00+482.2%+60.3%$71.41M$820,000.000.0040Short Interest ↓UNCYUnicycive Therapeutics3.0371 of 5 stars$0.69+3.3%$5.50+701.4%-28.4%$71.24M$680,000.00-0.719 Related Companies and Tools Related Companies BGM Alternatives RANI Alternatives AADI Alternatives IKNA Alternatives INCR Alternatives ANL Alternatives AVTE Alternatives PMVP Alternatives AVTX Alternatives UNCY Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYTH) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
